Sandoz Group (SDZNY) News Today $43.90 -1.69 (-3.71%) (As of 12/2/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Sandoz Group (OTCMKTS:SDZNY) Trading Up 0.8% - Should You Buy?Sandoz Group (OTCMKTS:SDZNY) Trading 0.8% Higher - Still a Buy?November 26, 2024 | marketbeat.comAgomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of DirectorsNovember 18, 2024 | businesswire.comSandoz receives EC approval for AfqlirNovember 16, 2024 | markets.businessinsider.comSandoz : EC Approves Afqlir 2 Mg Vial Kit & Pre-filled Syringe For Intravitreal InjectionNovember 15, 2024 | markets.businessinsider.comSandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolioNovember 15, 2024 | globenewswire.comSandoz price target raised to CHF 36 from CHF 33 at Deutsche BankNovember 6, 2024 | markets.businessinsider.comSandoz price target raised to CHF 39 from CHF 38 at BerenbergNovember 2, 2024 | markets.businessinsider.comSandoz price target raised to CHF 35 from CHF 32 at Morgan StanleyNovember 1, 2024 | markets.businessinsider.comSandoz reports third-quarter and nine-month 2024 salesOctober 30, 2024 | globenewswire.comSDZNY Sandoz Group AG ADROctober 26, 2024 | seekingalpha.comJ.P. Morgan Sticks to Their Buy Rating for Sandoz Group Ltd (SDZXF)October 22, 2024 | markets.businessinsider.comSandoz price target raised to CHF 43 from CHF 36.50 at JPMorganOctober 22, 2024 | markets.businessinsider.comSandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolioOctober 11, 2024 | globenewswire.comSandoz Canada achieves carbon neutral certification for its commercial operationsOctober 7, 2024 | globenewswire.comUnitedHealth Follows Competitors, Replaces Humira with Lower-Cost BiosimilarsSeptember 12, 2024 | benzinga.comKepler Capital Keeps Their Buy Rating on Sandoz Group Ltd (SDZXF)September 6, 2024 | markets.businessinsider.comSandoz Plans First GLP1 Generic Drug Launch in Canada in 2026September 3, 2024 | bloomberg.comIntroducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian marketAugust 13, 2024 | theglobeandmail.comUK to See First Inflation Rise This Year, Bolstering BOE CautionAugust 12, 2024 | uk.finance.yahoo.comSandoz Group: Sandoz receives FDA approval for Enzeevu (aflibercept-abzv), further strengthening US biosimilar positionAugust 12, 2024 | finanznachrichten.deSandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar positionAugust 12, 2024 | globenewswire.comSandoz Raises Sales Growth Target as Copycat Drugs FlourishAugust 8, 2024 | bloomberg.comSandoz Group AG (SDZNY) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | seekingalpha.comSandoz Group: Sandoz reports second-quarter sales and half-year 2024 resultsAugust 8, 2024 | finanznachrichten.deSandoz H1 Profit Down; Lifts FY24 Sales View, Backs Core Margin Forecast; Names New ExecutivesAugust 8, 2024 | markets.businessinsider.comSandoz reports second-quarter sales and half-year 2024 resultsAugust 8, 2024 | globenewswire.comSandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseasesJuly 25, 2024 | globenewswire.comSandoz Group AGJuly 19, 2024 | wsj.com3 Spinoff Stocks You Should Buy Now: July 2024July 15, 2024 | investorplace.comFDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in USJuly 1, 2024 | globenewswire.comSandoz Gets European Marketing Approval for Osteoporosis, Bone Disease TreatmentsMay 22, 2024 | marketwatch.comSandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in EuropeMay 22, 2024 | globenewswire.comEx-Sandoz exec gets probation for price-fixing after cooperation dealMay 15, 2024 | reuters.comBiosimilars Boosts Sandoz Q1 Sales; Backs Annual Sales OutlookMay 7, 2024 | markets.businessinsider.comSandoz reports first quarter 2024 salesMay 7, 2024 | globenewswire.comSandoz Group AG goes ex dividend tomorrowMay 2, 2024 | msn.comSandoz Reaches Agreement With Amgen Resolving All Patent LitigationApril 30, 2024 | marketwatch.comSandoz, Amgen reach agreement resolving patent litigation over biosimilarsApril 30, 2024 | msn.comShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AGApril 30, 2024 | globenewswire.comSandoz reaches agreement with Amgen over patent disputeApril 30, 2024 | reuters.comSandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilarsApril 30, 2024 | globenewswire.comAmgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelledApril 29, 2024 | msn.comSandoz : Pyzchiva Approved In Europe For Gastroenterology, Dermatology, And Rheumatology TreatmentsApril 22, 2024 | markets.businessinsider.comSandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offeringApril 22, 2024 | globenewswire.comSandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicinesMarch 21, 2024 | globenewswire.comSandoz Group Non-GAAP EPS of $2.20, revenue of $9.65B; initiates FY24 and long-term outlookMarch 14, 2024 | msn.comThe Cultivated B Introduces n!Biomachines: Fit-For-Purpose Bioreactors Designed to Easily and Affordably Scale Cellular AgricultureMarch 13, 2024 | theglobeandmail.comSandoz reports fourth quarter 2023 sales and full-year 2023 resultsMarch 13, 2024 | globenewswire.comSandoz Group: Sandoz receives FDA approval for first and only denosumab biosimilarsMarch 6, 2024 | finanznachrichten.deSandoz receives FDA approval for first and only denosumab biosimilarsMarch 5, 2024 | globenewswire.com Get Sandoz Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SDZNY and its competitors with MarketBeat's FREE daily newsletter. Email Address This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. SDZNY Media Mentions By Week SDZNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SDZNY News Sentiment▼0.000.87▲Average Medical News Sentiment SDZNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SDZNY Articles This Week▼01▲SDZNY Articles Average Week Get Sandoz Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SDZNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ATLKY News SHECY News KDDIY News ITOCY News CNSWF News MURGY News VCISY News GLNCY News CMPGY News BCMXY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SDZNY) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sandoz Group AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Sandoz Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
